Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?"

Dig Liver Dis. 2021 Mar;53(3):385-386. doi: 10.1016/j.dld.2021.01.014. Epub 2021 Jan 25.
No abstract available

Keywords: Cardiovascular; Fibrosis marker; NAFLD; Primary care; Primary prevention.

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Heart Disease Risk Factors
  • Humans
  • Liver Cirrhosis
  • Non-alcoholic Fatty Liver Disease*
  • Risk Factors